Bristol Myers Squibb will become responsible for the development and any marketing of DF6002 and its related products worldwide ... it plans to advance R&D in oncology and haematology and is ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.

Overall, BMS reported a 2% rise in second-quarter revenues to $11.9 billion, led once again by Opdivo and anti-thrombotic drug Eliquis (apixaban) but backed by a series of new products that ...

The European Medicines Agency’s Committee for Medicinal Products for Human ... Anne Kerber, BMS’ senior vice president for haematology, oncology, and cell therapy, said: “The positive ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology ...